Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed histologically confirmed stage I-III, ER, PR and HER2 negative invasive breast cancer as defined by the ASCO CAP guidelines for whom systemic chemotherapy would be indicated based on physician judgment following standard NCCN practice guidelines.~2. Willing and able to provide written informed consent for voluntary participation in the trial.~3. Willing to undergo a baseline tumor core needle biopsy and blood draws for correlative science studies.~4. Eighteen years of age or older on the day of signing informed consent.~5. Female subjects must either be of non-reproductive potential or must have a negative urine or serum pregnancy test upon study entry.~6. Patients should have adequate organ function to tolerate chemotherapy, as defined by:~   * peripheral granulocyte count of \> 1,500/mm3~  * platelet count \> 100,000/mm3~  * hemoglobin \>9 g/dL~  * total bilirubin \< 1.5 x upper limit of normal (ULN)~  * aspartate aminotransferase (AST) and alanine aminotransferase (ALT) each \< 1.5 x ULN~  * serum creatinine \< 1.5 x ULN or serum creatinine clearance \< 50mL/min~  * INR/PT/PTT each \< 1.5 x ULN~  * TSH within normal limits~Exclusion Criteria:~1. Patients who underwent partial excisional biopsy or lumpectomy, segmental mastectomy or modified radical mastectomy or sentinel node.~2. Patients for whom anthracycline, paclitaxel or antibody therapies are contraindicated.~3. Patients with active autoimmune disease or documented autoimmune disease within 2 years. Patients with hypothyroidism that is clinically stable and have normal TSH levels with hormone replacement, or patients with vitiligo or psoriasis not requiring treatment remain eligible for the study.~4. Active or prior documented inflammatory bowel disease (Crohn's disease, ulcerative colitis).~5. Patients with known active hepatitis B or C or HIV infection or with history of tuberculosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MEDI4736 (Type: EXPERIMENTAL): The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).